Reviewing Seattle Genetics Inc. (SGEN)’s and NuCana plc (NASDAQ:NCNA)’s results

Since Seattle Genetics Inc. (NASDAQ:SGEN) and NuCana plc (NASDAQ:NCNA) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation of both companies.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Seattle Genetics Inc. 72 15.17 N/A -1.75 0.00
NuCana plc 12 0.00 N/A -0.49 0.00

Table 1 highlights Seattle Genetics Inc. and NuCana plc’s gross revenue, earnings per share and valuation.

Profitability

Table 2 shows us the return on equity, net margins and return on assets of both businesses.

Net Margins Return on Equity Return on Assets
Seattle Genetics Inc. 0.00% -21.4% -18%
NuCana plc 0.00% 0% 0%

Liquidity

Seattle Genetics Inc. has a Current Ratio of 3 and a Quick Ratio of 2.7. Competitively, NuCana plc’s Current Ratio is 15 and has 15 Quick Ratio. NuCana plc’s better ability to pay short and long-term obligations than Seattle Genetics Inc.

Analyst Ratings

The following table shown below contains the ratings and recommendations for Seattle Genetics Inc. and NuCana plc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Seattle Genetics Inc. 0 1 2 2.67
NuCana plc 0 0 1 3.00

$79.75 is Seattle Genetics Inc.’s average price target while its potential upside is 12.23%. On the other hand, NuCana plc’s potential upside is 114.82% and its average price target is $20. Based on the results shown earlier, NuCana plc is looking more favorable than Seattle Genetics Inc., analysts opinion.

Institutional & Insider Ownership

The shares of both Seattle Genetics Inc. and NuCana plc are owned by institutional investors at 0% and 38.7% respectively. Seattle Genetics Inc.’s share owned by insiders are 1.1%. Comparatively, insiders own roughly 15.36% of NuCana plc’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Seattle Genetics Inc. 2.91% 10.77% 13% 0.77% 8.86% 33.62%
NuCana plc 5.77% -18.47% -42.6% -28.84% -57.21% -40.62%

For the past year Seattle Genetics Inc. had bullish trend while NuCana plc had bearish trend.

Summary

NuCana plc beats Seattle Genetics Inc. on 6 of the 9 factors.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML); ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL. In addition, it is involved in developing SEA-CD40 that is in Phase I clinical trial for patients with solid tumors and hematologic malignancies; SGN-CD19B, which is in Phase I clinical trial ongoing for patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; SGN-CD123A that is in Phase I trial for patients with relapsed or refractory AML; SGN-CD352A, which is in Phase I clinical trial for patients with relapsed or refractory multiple myeloma; SGN-2FF that is in Phase I clinical trial for patients with advanced solid tumors; and ASG-15ME that is in Phase I clinical trial for patients with urothelial cancer. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc.; and Unum Therapeutics, Inc., as well as has co-development agreement with Agensys, Inc. and Genmab A/S. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.

NuCana plc, a biopharmaceutical company, engages in the development of products for the treatment of cancer. The company is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; that is in Phase Ib clinical trials for the treatment of recurrent ovarian cancer; in Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer. The company is also developing NUC-3373, which is in Phase I clinical trials for the treatment of patients with advanced solid tumors, as well as for the treatment of colorectal and breast cancer; and NUC-7738, a nucleoside analog that is in preclinical studies for the treatment of solid tumors and hematology. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. The company was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.